U.S. delays Novartis diabetes drug
14th Nov 2006, 07:28 GMT
Novartis, one of the world's biggest drug makers, said Monday that U.S. regulators delayed the approval of the experimental diabetes pill Galvus after the company submitted more information on the safety of the product.
U.S. delays Novartis diabetes drug related news:
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- Novartis diabetes drug delayed — FT.com - Companies
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- Delay for FDA approval of diabetes drug — WISTV - Health
- Diabetes drug may cut heart risks — MSNBC.com: Health
- Diabetes drug may reduce cardiovascular risks — EurekAlert! - Medicine and Health
- Diabetes drug stalls heart disease — United Press International - Health Business
Latest news from Marketplace by Bloomberg - International Herald Tribune:
- Bids set for Singapore aircraft leaser
- Li Ka-shing charities buy stake in PCCW
- Around the Markets: Yen lures central banks
- Tesco suspends opening of stores in Thailand
- DLF to restart stalled IPO in next quarter
- Asian investors turn to European bonds
- Agile Property shares sold
- Viewpoint: Cutting a tax knot in India
- Briefly
- Currencies